Drug Trial Radar · NCT05262270
Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2)
Last checked: Nov 20, 2026Latest source record: Oct 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
427
Actual
Start
Apr 18, 2023
Primary completion
Jun 27, 2025
Study completion Jul 21, 2025
Sponsor
- Lead sponsor
- University of Texas Southwestern Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- National Institute on Drug Abuse (NIDA)
- First posted
- Mar 2, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an 8-week, double-blind, randomized placebo-controlled trial of the efficacy of a combination of extended-release naltrexone (XR-NTX) and extended-release buprenorphine (XR-BUP) compared to matched placebo injections (PBO-Inj) for the treatment of cocaine use disorder (CUD).
Conditions
- Cocaine Use Disorder
Interventions
Extended-Release NaltrexoneDrug
XR-NTX (Extended-Release Naltrexone) doses of 380mg (Weeks 0, 3 and 6) via intramuscular (IM) injections in the gluteus.
Extended Release BuprenorphineDrug
Extended-Release buprenorphine (XR-BUP) two doses of 300mg XR-BUP (Weeks 0, 4) via subcutaneous injections in the abdomen. Option for 100mg at Weeks 3 and 6 (if needed to alleviate side effects).
Placebo (PLB) Injectable matched to XR-NTXDrug
3 doses of intramuscular injections (Week 0, 3, 6)
Placebo (PLB) Injectable matched to XR-BUPDrug
2 doses of subcutaneous injections (Week 0, 4)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of Cocaine-negative UDSTime frame: Week 5 up to Week 8
Locations
12 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham
Birmingham, Alabama
University of Arkansas for Medical Sciences
Little Rock, Arkansas
UCLA Vine Street Clinic
Los Angeles, California
Center on Substance Use and Health (CSUH)
San Francisco, California
Cove Behavioral Health
Tampa, Florida
University of Illinois at Chicago
Chicago, Illinois
University of Chicago
Chicago, Illinois
Mountain Manor Treatment Center
Baltimore, Maryland
Berman Center for Outcomes and Clinical Research at Hennepin Healthcare
Minneapolis, Minnesota
Addictions Institute of Mount Sinai
New York, New York
UTSW Medical Center, Center for Depression Research and Clinical Care
Dallas, Texas
University of Texas Health San Antonio
San Antonio, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.